Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 7;11(6):e006747. doi: 10.1136/jitc-2023-006747

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Overall survival in patients who progressed on prior anti-PD(L)1. (A) Kaplan-Meier estimates of overall survival (OS) for patients who progressed on prior anti-PD(L)1 therapy treated with tebentafusp in combination with durvalumab (Arm 1; n=34; blue) or durvalumab and tremelimumab (Arm 3; n=24; green). Events are deaths due to any cause. Patients not known to have died at the time of analysis are censored. For patients receiving combination tebentafusp and durvalumab (Arm 1), the median OS was 18.4 (95% CI: 13.1 to 22.3) months with a 1-year OS rate of 73% (95% CI: 65% to 80%). For patients receiving triplet therapy (Arm 3), the median OS was 17.8 (95% CI: 14.6 to 21.7) months with a 1-year OS rate of 78% (95% CI: 70% to 87%). (B) Kaplan-Meier estimates of OS for patients who had a best response of progressive disease while on prior anti-PD(L)1 (refractory; n=19; blue) or had a best response of either stable disease (n=17) or partial response/complete response (n=17) and then had disease progression on prior anti-PD(L)1 (relapsed n=34; red). For patients refractory to prior anti-PD(L)1, the median OS was 18.4 (95% CI: 7.2 to 28.6) months with a 1-year OS rate of 60% (95% CI: 49% to 72%). For patients relapsed on anti-PD(L)1, the median OS was 17.7 (95% CI: 15.4 to 21.7) months with a 1-year OS rate of 82% (95% CI: 75% to 89%).